Acne vulgaris is a common dermatological condition in adult women, often influenced by hormonal factors. Androgens such as dehydroepiandrosterone sulfate (DHEAS) can stimulate sebaceous gland activity, while gonadotropins (FSH and LH) reflect ovarian and hypothalamic-pituitary axis function. Although systemic isotretinoin is highly effective in severe or treatment-resistant acne, variability in treatment response has been observed among female patients. The role of baseline hormonal levels in predicting isotretinoin response remains unclear. Identifying hormonal predictors of treatment response may improve patient stratification and personalized management. Aim of the study is to evaluate whether baseline serum levels of DHEAS, FSH, and LH are associated with clinical response to systemic isotretinoin in women aged 18 years and older with acne vulgaris.
Female patients aged ≥18 years.
Clinical diagnosis of moderate to severe acne vulgaris.
Planned initiation of systemic isotretinoin therapy.
Ability to provide informed consent
Use of hormonal therapy (oral contraceptives, antiandrogens, systemic corticosteroids) within the last 3 months.
Contraindications to isotretinoin therapy.
Female patients aged 18-40 with moderate to severe acne vulgaris who are planned to recieve isotretinoin treatment.
Cohort
Prospective
Not listed
treatment response of patients with normal and elevated levels of hormone
The number of months and doses during which no new acne breakouts occur after starting isotretinoin treatment will be recorded.
Click on the lead sponsor to view all of their trials.
